Atoltivimab + Odesivimab + Maftivimab OverviewAtoltivimab/maftivimab/odesivimab, developed as REGN-EB3 and sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus). It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals. The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are al...
Read more Atoltivimab + Odesivimab + Maftivimab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Atoltivimab/maftivimab/odesivimab
Recent Atoltivimab + Odesivimab + Maftivimab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Atoltivimab + Odesivimab + Maftivimab
- Solution: 16.7mg/1ml
Drugs with one or more similar ingredients: (1 result)
- INMAZEB Atoltivimab + Odesivimab + Maftivimab